To Study the Efficacy and Safety of TIPS (Trans Intrahepatic Portosystemic Shunt) Versus Self Expanding Metallic Stent (SEMS) in the Management of Refractory Variceal Bleed in Cirrhotics.
Primary Purpose
Liver Cirrhoses
Status
Unknown status
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Trans Intrahepatic Portosystemic Shunt
Self Expanding Metallic Stent
Vasoactive Agent
Sponsored by
About this trial
This is an interventional treatment trial for Liver Cirrhoses
Eligibility Criteria
Inclusion Criteria:
- Consecutive patients of cirrhosis aged 18-70 years presenting with acute variceal Bleeding, who on endoscopy fail to control bleed or rebleeds within 5 days will be randomized.
Exclusion Criteria:
- Bleeding from non-variceal source
- Coagulopathy related bleed
- Bleeding from Gastric varices
- Any malignancy including HCC
- Main Portal vein thrombosis
- Patients in refractory shock
- Patients with severe cardiopulmonary disease
- Grade 4 Hepatic encephalopathy
- MELD > 25
- Multiorgan failure
- Active sepsis
- Pregnancy
- Failure to give consent
Sites / Locations
- Institute of Liver & Biliary SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
TIPS + Vasoactive Drug
SEMS + Vasoactive Drug
Arm Description
Outcomes
Primary Outcome Measures
Survival in both groups
Secondary Outcome Measures
Re-bleeding in both groups for 5 days from end of therapy
Rebleeding in both groups
Decompensation in both groups in the form of ascites or Hepatic Encephalopathy
Adverse events in both groups
Worsening of liver severity score in both groups.
Full Information
NCT ID
NCT03827681
First Posted
January 31, 2019
Last Updated
March 9, 2020
Sponsor
Institute of Liver and Biliary Sciences, India
1. Study Identification
Unique Protocol Identification Number
NCT03827681
Brief Title
To Study the Efficacy and Safety of TIPS (Trans Intrahepatic Portosystemic Shunt) Versus Self Expanding Metallic Stent (SEMS) in the Management of Refractory Variceal Bleed in Cirrhotics.
Official Title
A Randomised Controlled Trial to Study the Efficacy and Safety of TIPS (Trans Intrahepatic Portosystemic Shunt) Versus Self Expanding Metallic Stent (SEMS) in the Management of Refractory Variceal Bleed in Cirrhotics.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
February 6, 2019 (Actual)
Primary Completion Date
June 30, 2020 (Anticipated)
Study Completion Date
June 30, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A total of 50 patients will be enrolled and will be randomized into either Group A(TIPS) or Group B (SEMS).
Primary end point of the study will be to compare efficacy of TIPS versus SEMS for survival at 6 week or Early re Bleed. All enrolled patients will also undergo HVPG measurement at baseline to stratify risk of failure to control bleed or early re-bleed.
Patient will be monitored for 5 days for re bleed, complications of therapy, worsening of Liver function tests and scores and efficacy of either treatment modality over other. Patient will be followed for 6 weeks to see for the primary end point.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cirrhoses
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TIPS + Vasoactive Drug
Arm Type
Experimental
Arm Title
SEMS + Vasoactive Drug
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Trans Intrahepatic Portosystemic Shunt
Intervention Description
The most common approach is through the right internal jugular approach.
After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.
A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'
A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein.
Intervention Type
Procedure
Intervention Name(s)
Self Expanding Metallic Stent
Intervention Description
At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.
The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.
The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.
After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide.
Intervention Type
Drug
Intervention Name(s)
Vasoactive Agent
Intervention Description
Vasoactive Agent
Primary Outcome Measure Information:
Title
Survival in both groups
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Re-bleeding in both groups for 5 days from end of therapy
Time Frame
5 days
Title
Rebleeding in both groups
Time Frame
6 weeks
Title
Decompensation in both groups in the form of ascites or Hepatic Encephalopathy
Time Frame
6 weeks
Title
Adverse events in both groups
Time Frame
6 weeks
Title
Worsening of liver severity score in both groups.
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- Consecutive patients of cirrhosis aged 18-70 years presenting with acute variceal Bleeding, who on endoscopy fail to control bleed or rebleeds within 5 days will be randomized.
Exclusion Criteria:
Bleeding from non-variceal source
Coagulopathy related bleed
Bleeding from Gastric varices
Any malignancy including HCC
Main Portal vein thrombosis
Patients in refractory shock
Patients with severe cardiopulmonary disease
Grade 4 Hepatic encephalopathy
MELD > 25
Multiorgan failure
Active sepsis
Pregnancy
Failure to give consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Shushrut Singh, MD
Phone
01146300000
Email
drsushrut20@gmail.com
Facility Information:
Facility Name
Institute of Liver & Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Shushrut Singh, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
To Study the Efficacy and Safety of TIPS (Trans Intrahepatic Portosystemic Shunt) Versus Self Expanding Metallic Stent (SEMS) in the Management of Refractory Variceal Bleed in Cirrhotics.
We'll reach out to this number within 24 hrs